116 results about "Ascitic fluid" patented technology

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

The invention discloses a method for separating rare cells from peripheral blood and a kit using the same. The method integrates a negative enrichment technology and a density gradient centrifugation technology, has the advantages of high recovery rate, simpleness, and convenience, and generates little damage to rare cells in peripheral blood. By using the provided kit, tumor cells such as breast cancer cells can be separated from peripheral blood through the separation method. The kit and method can also be applied to early diagnosis, relapse monitoring, and drug effect evaluation, can be used to separate rare cells in body liquids such as pleural fluid, ascitic fluid, and the like, and have a wide application prospect.

The invention provides a method for in-vitro expansion of CD8<+>T cells. The method comprises steps as follows: TIL (tumor infiltrating lymphocyte) cells are extracted from a malignant pleural and peritoneal effusion source, cytokines IL-2, CD3McAb and PD-1 monoclonal antibodies are added to a TIL cell culture medium, the concentration of the IL-2 is 300-1,000 U/ml, the concentration of the CD3McAb is 10-50 ng/ml, and the concentration of the PD-1 monoclonal antibodies is 50-200 ng/ml. The cell factor combination adopted by the method can increase the TIL cell expansion multiple, effectively inhibit the negative regulation effect of Treg cells on the CD8<+>T cells and promote the anti-tumor effect.

The invention discloses a carbendazim monoclonal antibody, a preparation method and an application thereof. The carbendazim monoclonal antibody is prepared by a mouse hybridoma cell strain MC-3 with a preservation number of CGMCC N0.4575 and the preparation method is as follows: (1) introducing ninth amino acid residue of carbendazim into one amino group to obtain the carbendazim modified by the amino and coupling the carbendazim modified by the amino with a carrier protein to obtain a complete antigen A; (2) immunizing a mouse by the complete antigen A obtained in step (1), taking splenocyteof the immune mice to fuse with a mouse myeloma cell to screen out a positive hybridoma cell strain; extensively culturing the positive hybridoma cell strain and injecting the positive cell strain into a homologous mouse abdominal cavity to induce to generate ascitic fluid and to obtain more carbendazim monoclonal antibodies. The Carbendazim monoclonal antibody can be used for detecting the carbendazim.

The invention discloses a primer system for detecting 10 common pathogenic bacteria of clinical infection. The detection system is used for detecting blood or body fluid (pleural fluid, ascitic fluid,drainage fluid, synovial fluid and cerebrospinal fluid) infected samples of patients infected by the pathogenic bacteria; detection results are combined with other clinical indicators, reference canbe provided for early diagnosis for clinicians and rational use of antibiotics, and treatment delaying and nonstandard use of the antibiotics are avoided. Virulence factor gene loci of 10 differentpathogenic bacteria can be simultaneously detected in two reaction systems; compared with sequencing, real-time fluorescence quantitative PCR and other technologies, the cost is lower, the operation is more convenient, and the accuracy and sensitivity are improved.

The invention relates to an anti-rabbit hemorrhagic disease virus (RHDV)VP60 albumen monoclonal antibody, and belongs to the technical field of biology. An SP2/0 myeloma cell and a BALB/c mouse splenic cell immunized by utilizing RHDV to recombine VP60 albumen undergo cell fusion, are selectively cultured by an HAT culture medium and undergo double ELISA screening by utilizing the recombined VP60 albumen and RHDV; the obtained cell culture supernatant is checked up and screened respectively to obtain a hybrid tumor cell strain A3C which can stably excrete the anti-RHDV VP60 albumen monoclonal antibody; the ascitic fluid ELISA titer of the A3C is detected to be 1:327,600; and according to identification, the monoclonal antibody can specifically combine the expressed recombined VP60 albumen as well as the RHDV, and one single reaction strip appears in both specific combinations, thereby proving that the anti-RHDV VP60 albumen monoclonal antibody is a VP60 specific antibody of the RHDV capsid albumen.

The invention aims to provide an efficient amplification method of TILs serving as sources of cancerous pleural effusion. The TILs prepared with the method have the advantages of being high in multiplication speed, large in number, high in cell activity and the like. The method is mainly characterized in that by utilizing a cultivation bottle coated by laminin protein and fibronectin, the TILs are cultivated. The adsorption effect of the two kinds of protein can make cells in half-adherence state, therefore, the cells are favorable for being stimulated by various factors, and the two kinds of protein has the multiplication promoting effect on the TILs; by using a resistant OX-40 monoclone antibody, co-stimulatory signals of CD3+CD8+T cell subgroups in the TILs can be stimulated, cell activation is promoted, the expression of cell perforin and granular enzyme is improved, and the killing capacity of the TILs is enhanced. So far, the study report that the laminin protein, the fibronectin and the resistant OX-40 monoclone antibody are combined and used for preparing the TILs has not been given, and the method for increasing the cell number and improving the killing activity by adding the three factors in preparation of the TILs is put forward for the first time.

An exterior-applied Chinese medicine for treating hepatocirrhosis ascites is prepared from 7 Chinese-medicinal materials including astragalus root (or rhubarb), cloves, borneol, musk, etc. Its preparing process is also disclosed.

The invention provides a kit for detecting serum amyloid A content and a preparation method and detection method thereof and belongs to the field of medical detection. The kit comprises a hemolytic agent R1 and a latex reagent R2 which are independent with each other. The latex reagent R2 comprises latex coated with a serum amyloid A antibody. The latex coated with the serum amyloid A antibody isprepared from latex having particle sizes of 60-130nm and coated with the anti-serum amyloid A1 antibody and latex having particle sizes of 190-220nm and coated with the anti-serum amyloid A2 antibodythrough mixing. The invention also provides a preparation method and a detection method of the kit for detecting serum amyloid A content. The kit can detect whole blood, serum, a cerebrospinal fluidand a pleuroperitoneal fluid, utilizes a small amount of samples, is free of separation or pretreatment, can be directly used for detection and has good sample compatibility.

The present invention provides methods for culturing primary cells and tissues from a subject in the presence of the subject's own serum, ascites or pleural effusion fluid. Methods of treating cancer, and screening for the effectiveness or toxicity of drugs are also provided herein.

The invention relates to a rat transplantable lung cancer model establishing method including the following steps: Walker-256 cell ascitic fluid is prepared; Walker-256 cell is inoculated into SD rat (Sprague-Dawley rat) lung; after anesthesia of a SD rat, left part of thoracic cavity of the SD rat is disinfected by use of povidone-iodine, Walker-256 cell suspension and Matrigel in same volume are mixed evenly on the ice to obtain a mixed solution, the mixed solution is slowly injected between 5th rib and 6th rib at left lung into the left lung by use of an injector, the puncture depth is 0.6-0.8 cm, after the injection, a needle is stopped for 10 s, and then is pulled out slowly, and after the rat is grown for 14 days, a transplantable lung cancer model is established. According to the method, the damage to the rat is small, the Walker-256 cell can be directly transplanted into the left lung only by use of a generally anaesthetized rat, formation of tumor lesion part is clear, the tumor lesion is single and controllable in size, and the method also has the advantages of simple preparation, high tumor formation rate, low animal mortality and the like.

Provided are a stock solution concentrating device, a stock solution treatment device and a circulation-type treatment device that can prevent the deposition of cells and the like on a filtration member and that can continuously filter and concentrate a stock solution such as pleural and ascitic fluid or blood plasma. The stock solution concentrating device concentrates a stock solution such as pleural and ascitic fluid or blood plasma to form a concentrated solution, and is equipped with: a filter (10) having a filtration member that filters the stock solution; a concentrator (20) to which the filtrate which has been filtered is supplied, and which concentrates the filtrate to form a concentrated solution; and a stock solution supply unit that supplies the stock solution to the filter (10). The stock solution supply unit has a supply amount adjustment function for adjusting the amount of the stock solution supplied to the filter.

The invention relates to a chloramphenicol-resistant monoclonal antibody, which is mainly used for detecting chloramphenicol residue in livestock products and milk products. The chloramphenicol-resistant monoclonal antibody is secreted from a hybridoma cell line 7C10; and the preparation method comprises the following steps of: coupling EDC-activated chloramphenicol and carrier protein to obtain immunogen and coating antigen; performing intraperitoneal injection of mouse immunogen and enhancing the immunity; screening out a mouse who is subjected to immunity enhancement and has high serum titer; fusing spleen cells and SP2/0 myeloma cells; performing sub-clone to obtain the monoclonal antibody hybridoma cell line 7C10 capable of stably secreting the chloramphenicol; performing intraperitoneal injection on the mouse with the hybridoma cell line 7C10; collecting ascitic fluid; and performing liquid-phase chromatographic purification to obtain the chloramphenicol-resistant monoclonal antibody 7C10'. The chloramphenicol-resistant monoclonal antibody has the advantages of high specificity, high flexibility and affinity, large-scale production and effect of quickly and sensitively detecting the chloramphenicol residue in foods such as milk, meats, aquatic products and the like.

The invention discloses a medicine for treating ascites due to liver cancer. The medicine comprises the following components in parts by weight: 15-19 parts of radix bupleuri, 15-19 parts of bighead atractylodes rhizome, 20-24 parts of white peony root, 15-19 parts of dried tangerine peel, 10-14 parts of chrysanthemum morifolium, 10-14 parts of Chinese angelica, 15-19 parts of salviae miltiorrhizae, 20-24 pats of fiveleaf akebia fruit, 5-9 parts of safflower, 15-19 parts of poria, 20-24 parts of sculellaria barbata, 20-24 parts of rhizoma sparganic, 30-34 parts of polygonum cuspidatum, 10-14 parts of moutan bark, 20-24 parts of dandelion, 20-24 parts of solanum nigrum, 20-24 parts of oriental wormwood, 20-24 parts of curcuma zedoary, 20-24 parts of aspongopus, 20-24 parts of indian iphigenia bulb, 10-14 parts of spina gleditsiae, 20-24 parts of manyleaf paris rhizome, 10-14 parts of fructus aurantii, 15-19 parts of artemisia anomala, 20-24 parts of raw oyster, 20-24 parts of turtle shell, 10-14 parts of costustoot, 15-19 parts of codonopsis pilosula, 30-34 parts of selfheal, 15-19 parts of salvia chinensis, 15-19 parts of verbena, 5-9 parts of rhizoma alismatis, 5-9 parts of polyporus umbellatus, 10-14 parts of plantain seed, 10-14 parts of frankincense, 10-14 parts of myrrh, 10-14 parts of corydalis tuber, 10-14 parts of radix curcumae, 10-14 parts of toad skin, 5-9 parts of greater celandine herb, 5-9 parts of szechwan Chinaberry fruit, 10-14 parts of sappanwood, 3-7 parts of radix phytolaccae, 10-14 parts of paniculate swallowwort root, and 3-7 parts of semen pharbitidis. The effective rate of the medicine in treating ascites due to liver cancer can be 73 percent.

The invention discloses a preparation method of an anti-AMH specific antibody. The method comprises the steps that firstly, a pCMV3 expression plasmid containing an AMH encoding sequence is constructed, a CHO cell is transfected, a cell culture supernatant is collected and purified through a Ni column, and purified AMH recombinant protein is obtained for standby use; the prepared AMH recombinant protein is used as an immunogen for immunizing a Balb/c mouse, after it is detected that the serum titer of the mouse exceeds 1/8K through an ELISA indirect method, the spleen of the immunized mouse isfused with a myeloma cell NS1 of the mouse, a hybridoma cell is subjected to subcloning screening three times through the ELISA indirect method, and a monoclonal hybridoma cell secreting anti-AMH isobtained; the enterocoelia of the mouse is injected with the hybridoma cell, ascitic fluid is collected and purified, and the anti-AMH specific monoclonal antibody is obtained. The preparation methodis simple, the prepared antibody has high specificity and is applied to a kit for detecting the content of AMH in humans, the detection result is hardly influenced by animal serum, and the reliable basis can be provided for clinical diagnosis and treatment by doctors.

The invention provides a set of primer for noninvasively detecting EML4-ALK fusion gene based on vesicles. The invention also provides a probe and a primer for detecting the EML4-ALK fusion gene through qPCR or digital PCR; the sequence is shown as SEQ ID NO:1-5. The primer and the probe are used for building a noninvasive, fast and high-sensitivity EML4-ALK fusion gene mutation detection method based on vesicles. The detection method has the advantages that by aiming at body fluid specimens (including blood, hydrothorax, ascitic fluid, cerebrospinal fluid and the like), clinical specimens canbe easily obtained. The detection sensitivity of the method is high; EML4-ALK mutation containing 10 copies can be stably detected; the precise medicine use guide can be provided.

The invention relates to the technical field of ELISA detection kits, and particularly discloses a high-capacity asphalt/epoxy resin-based hard carbon negative electrode material and a preparation method of same. The kit includes a box body, in which two ELISA plates coated with anti-CD63 cloning antibody, an ELISA plate coated with anti-CA125 cloning antibody, 10 ml of HPR-labeled CA125 antibody,10 ml of HPR-labeled CD63 antibody, 20 ml of H2O2 being a color developing agent A solution, 20 ml of TMB being a color developing agent B solution, and two bottles of 5 ml of stop solution. Comparedwith the prior art, by means of the exosome ELISA method, an antigen of the ovarian cancer is quickly detected, thus completing early diagnosis on the ovarian cancer. The kit is high in detection accuracy and specificity and is extensive in detectable sample range, which may include serum, ascites, blood plasma, tissue liquid and the like. The kit is short in reaction period and has good effect.

The invention relates to a double-cross-linking chemical synthesis method of a citrinin-protein-coupled antigen and a preparation method of an anti-citrinin monoclonal antibody, belongs to the field of biotechnology. The synthesis method of the citrinin-protein-coupled antigen comprises the following steps that: the citrinin and a double-cross-linking agent (C2H3O)-(CH2)n-(C2H3O) react at first and is then coupled with a carrier, glycine is used for occlusion after reaction, and separation and purification are carried out finally, thereby obtaining the citrinin-carrier-coupled antigen. The preparation method of the anti-citrinin monoclonal antibody comprises the following steps: carrying out cell fusion and screening with the hybridoma technique to obtain a hybridoma cell line of the anti-citrinin monoclonal antibody with stable secretion, preparing ascitic fluid, and purifying, thereby obtaining the anti-citrinin monoclonal antibody. The invention has the advantages of mild preparation conditions, simple operation and controllable process. The obtained anti-citrinin monoclonal antibody has high specificity and high affinity, and can be further used for preparation of the enzyme linked immunosorbent assay kit or test paper card for citrinin detection.

The invention discloses a hybridoma cell strain excreting a monoclonal antibody (MAb) resisting a rice blackstreaked dwarf virus (RBSDV) and the application of the MAb. A coat protein (CP) of the RBSDV is expressed into antigen immune BALB/c mouse by a prokaryotic expression method, and the hybridoma cell strain 5G1 which can stably passage and excrete the MAb resisting the RBSDV is obtained through cell fusion, selection and cloning, wherein the preserving number is CGMCC No. 5537. Ascitic indirect enzyme-linked immuno sorbent assay (ELISA) valence of the 5G1 MAb is over 10<-6>, and the antibody type and the subtype are IgG1 and kappa chain. The antibody excreted by the cell strain and the coat protein of the RBSDV have specific immunobinding reaction. By the dot-ELISA detection method for detecting rice planthopper and the RBSDV in rice and established by using the 5G1 MAb as a core, the virus can be still detected when a single-head small brown rice planthopper is diluted to 1,600 microlitres and sick leaves are diluted (w/v, g/mL) in the proportion of 1:160. The preparation of the MAb resisting the RBSDV and the establishment of the detection method thereof provide technical and material support for the diagnosis, forecast and scientific prevention and control of rice viruses.

As an FAM19A4 protein is possibly related to various physiological and pathological conditions and plays an important role in the physiological and pathological conditions, and quantitative detectionof the soluble FAM19A4 protein in specific samples such as blood, body fluid and cell culture supernatant has significance. The invention firstly relates to an application of the FAM19A4 protein serving as a diagnosis marker of a disease including an infectious disease and an autoimmune disease. The invention further relates to a method and kit for quantitatively detecting the soluble FAM19A4 protein. According to the method and kit, the soluble FAM19A4 protein is detected through a micro-sphere solid carrier and a flow cytometry technique by the aid of the double-antibody sandwich method principle, and the method and kit can be used for quantitatively detecting the FAM19A4 protein in body fluids such as serum, plasma, urine, pleuroperitoneal fluids, joint fluids, cerebrospinal fluids, amniotic fluids and follicular fluids of a clinic patient, basic research and various biological samples such as cell culture fluids and mouse blood in a mouse model.

The invention provides a monoclonal antibody TBEF3 of tubercle bacillus-resistant secretory antigen target protein in early stage. The monoclonal antibody TBEF3 is prepared by the following steps: selecting a specific antigen peptide mouse; collecting sensitized mouse B lymphocyte and mouse myeloma cell to fuse; judging positive clones by using an enzyme linked immunosorbent assayelisa and an immunoblotting testing method; establishing a hybridoma cell line TBEF3 for secreting monoclonal antibody of tubercle bacillus-resistant secretory ESAT-6 in early stage; carrying out multiplication culturing on the positive cells and injecting to congenic mouse enterocoelia for induction of generation of ascitic fluid containing antibody; and carrying out collection and antibody affinity purification to obtain the monoclonal antibody TBEF3 of tubercle bacillus-resistant secretory antigen target protein in early stage. The invention also provides an application of the monoclonal antibody in testing the secretory antigen target protein of mycobacterium tuberculosis in early stage.

The present invention relates to a Chinese medicine Chuanjia Zigan powder for effectively curing the diseases of cirrhosis, ascites due to cirrhosis and hepatitis B with obvious therapeutic effect. Said Chinese medicine is made up by using 19 Chinese medicinal materials of sparganium root, curcuma tuber, capillaries, turtle shell, isatis root, coix seed and others through a certain preparation process. Its total effective rate is above 95% and its cure rate is above 85%.

The invention discloses an anti-goat IgM (Immunoglobulin M) [mu] chain monoclonal antibody, a hybridoma cell strain secreting the antibody and a purpose thereof. According to the anti-goat IgM (Immunoglobulin M) [mu] chain monoclonal antibody, secretory IgM protein is used as target protein; a complete open reading frame of a gene of an IgM [mu] chain is obtained through cloning; the open reading frame is sub-cloned to a prokaryotic expression vector; recombinant protein is purified by utilizing a nickel column; a female BALB/c mouse at an age of 6 to 8 weeks is immunized; when the titer of an antibody is 1 to 10,000 or above, the single-cell suspension of the splenocyte of the immunized mouse and a myeloma cell of a logarithmic growth phase are subjected to melt; the hybridoma cell strain secreting the anti-goat IgM [mu] chain monoclonal antibody is obtained by sieving; a hybridoma cell is injected into the abdominal cavity of a parous BALB/c mouse at the age of 6 to 8 weeks; abdominal dropsy is collected when the injection is carried out for approximately 7 days; the abdominal dropsy is purified by protein G/A agarose; a higher-purity anti-goat IgM [mu] chain monoclonal antibody is obtained. The monoclonal antibody provided by the invention is high in valence, can be used for detecting goat IgM, moreover, is hopeful for realizing the early screening and monitoring on multiple goat diseases, and has wide application range and social demand.

The invention provides a novel Avermectin resistant monoclonal antibody, hybridomas cell line excreting it and its preparing process, which comprises synthesizing artificial antigen AVM-BSA, immuning BALB/c mouse for five times, carrying out cell fusion to mouse spleen cells and SP2/O marrow tumor cells, using PEG1450 as fusion agent to screen positive fused cells, subcloning five times with limited dilution method, obtaining hybridomas cell lines 2F2 specifically secreting AVM antibody, whose micro-organism Deposit number is CGMCC NO.1413, injecting BALB/c mouse's abdominal cavity with the hybridomas cell, gathering ascitic fluid, centrifuging, gathering supernatant fluid, purifying and identifying to obtain the Avermectin resistant monoclonal antibody.